Abstract

Background: Lysine is an essential amino acid that is not synthesized within the body. It is synthesized in higher plants through a biochemical pathway. Many clinical trials have reported that amino acids play an important role in hastening the process of healing by improving the local blood supply as growth factors. Aims and Objectives: This study aimed to establish wound healing, efficacy, and tolerability of lysine cream (15%) in non-diabetic foot ulcer by Bates-Jensen wound assessment tool (BWAT).
Materials and Methods: A randomized, open-label, interventional, comparative, prospective parallel group study was conducted on 20 subjects (participants) with non-diabetic ulcer. Participants were divided into two groups, namely, control and test. The control group was treated with standard treatment and the test group was treated with standard therapy along with lysine cream (15%) twice daily. Participants were screened by BWAT.
Results: The 20 participants were allocated into two groups. The control group was treated with standard treatment (n = 10). The test group received standard treatment followed by lysine 15% cream. The mean ± standard deviation values indicate size and depth of the foot ulcer from the 1st week to 7th week. Both the groups showed significant decrease in the size and depth of the ulcer over the period of 7 weeks. Assessment of the 1st week showed that there is no significant decrease in the size of the ulcer. Overall mean difference of the control versus test groups indicated that the lysine-treated group significantly decreased both the parameters than the standard therapy (control). Conclusion: Treatment with lysine cream significantly improved wound healing in non-diabetic foot ulcer patients when compared to the standard therapy